BACKGROUND: Y-Box-binding protein-1 (YB-1) acts as a transcription factor for multiple genes and is linked to DNA replication and repair, cell proliferation and resistance to cytostatic drugs. PATIENTS AND METHODS: The prognostic value of YB-1 expression in primarily untreated malignant non-Hodgkin's lymphomas (NHLs) was examined using immunohistochemistry. RESULTS: Expression of YB-1 was detected in 48 out of 56 NHLs, and the immunohistochemical reaction was localized exclusively in the cytoplasm. Expression of YB-1 did not correlate with clinicopathological variables. Patients with higher YB-1 expression had shorter progression-free survival during the entire period of observation (p=0.0434), as well as in the course of 30 months' observation (p=0.0253). Additionally, in the course of 50 months' observation, patients with higher expression of YB-1 demonstrated a shorter overall survival time (p=0.0383) and a shorter progression-free survival (p=0.0309). CONCLUSION: Elevated YB-1 expression may represent a new unfavorable prognostic factor.
BACKGROUND:Y-Box-binding protein-1 (YB-1) acts as a transcription factor for multiple genes and is linked to DNA replication and repair, cell proliferation and resistance to cytostatic drugs. PATIENTS AND METHODS: The prognostic value of YB-1 expression in primarily untreated malignant non-Hodgkin's lymphomas (NHLs) was examined using immunohistochemistry. RESULTS: Expression of YB-1 was detected in 48 out of 56 NHLs, and the immunohistochemical reaction was localized exclusively in the cytoplasm. Expression of YB-1 did not correlate with clinicopathological variables. Patients with higher YB-1 expression had shorter progression-free survival during the entire period of observation (p=0.0434), as well as in the course of 30 months' observation (p=0.0253). Additionally, in the course of 50 months' observation, patients with higher expression of YB-1 demonstrated a shorter overall survival time (p=0.0383) and a shorter progression-free survival (p=0.0309). CONCLUSION: Elevated YB-1 expression may represent a new unfavorable prognostic factor.
Authors: Amina Kariminia; Sabine M Ivison; Vivian M Leung; Susanna Sung; Nicole Couto; Jacob Rozmus; Nina Rolf; Aru Narendran; Sandra E Dunn; Gregor S D Reid; Kirk R Schultz Journal: Oncol Lett Date: 2016-11-28 Impact factor: 2.967
Authors: Y Wu; K-Y Wang; Z Li; Y-P Liu; H Izumi; S Yamada; H Uramoto; Y Nakayama; K Ito; K Kohno Journal: Clin Transl Oncol Date: 2014-07-31 Impact factor: 3.405
Authors: Li Pu; Shi Jing; Guo Bianqin; Liu Ping; Liang Qindong; Liu Chenggui; Cheng Feng; Kuang Wenbin; Wang Qin; Dong Jinyu; Xia Qianfeng; Liu Yu; Tu Zhiguang Journal: Hepat Mon Date: 2013-07-03 Impact factor: 0.660
Authors: Asmus Heumann; Özge Kaya; Christoph Burdelski; Claudia Hube-Magg; Martina Kluth; Dagmar S Lang; Ronald Simon; Burkhard Beyer; Imke Thederan; Guido Sauter; Jakob R Izbicki; Andreas M Luebke; Andrea Hinsch; Frank Jacobsen; Corinna Wittmer; Franziska Büscheck; Doris Höflmayer; Sarah Minner; Maria Christina Tsourlakis; Thorsten Schlomm; Waldemar Wilczak Journal: Sci Rep Date: 2017-05-17 Impact factor: 4.379